MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
44.82
-2.20
-4.68%
After Hours: 44.70 -0.12 -0.27% 19:49 05/29 EDT
OPEN
46.54
PREV CLOSE
47.02
HIGH
46.77
LOW
43.59
VOLUME
4.73M
TURNOVER
0
52 WEEK HIGH
100.77
52 WEEK LOW
43.59
MARKET CAP
8.27B
P/E (TTM)
-33.8366
1D
5D
1M
3M
1Y
5Y
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
NASDAQ · 13h ago
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
NASDAQ · 1d ago
Exact Sciences to Participate in June Investor Conferences
Exact Sciences Corp. Is a leading provider of cancer screening and diagnostic tests. Exact Sciences management will participate in the following conferences and invited investors to participate by webcast. The webcasts can be accessed in the investor relations section of the company’s website.
Barchart · 1d ago
Weekly Report: what happened at EXAS last week (0520-0524)?
Weekly Report · 2d ago
Stocks Finish Higher on Hopes Inflation Pressures Will Dissipate
US stock indexes Friday settled higher. The broader market rose on positive corporate news. Deckers Outdoor closed up more than +14% after reporting Q4 net sales well above consensus. Strength in chip stocks bolstered by Nvidia’s results. Overseas stock markets in Europe and Japan settled lower.
Barchart · 5d ago
Guardant Stock Climbs As Cancer Test Strides Towards FDA Ok
The Wall Street Journal · 5d ago
Guardant jumps as trading resumes after FDA AdCom vote on cancer test
Guardant Health shares added 15% premarket as trading resumes after FDA AdCom vote on cancer test. FDA advisory committee backs company's Shield colorectal cancer screening test. The company's stock was halted for trading on Thursday as the agency reviewed the company's premarket approval application.
Seeking Alpha · 5d ago
Health Care Sector Update for 05/24/2024: GH, EXAS, VSTM, XLV, IBB
NASDAQ · 5d ago
More
About EXAS
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Webull offers Exact Sciences Corp stock information, including NASDAQ: EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.